Tucatinib with trastuzumab and oxaliplatin-based chemotherapy for untreated HER2-positive metastatic or unresectable colorectal cancer [TSID12353]

  • Awaiting development
  • GID-TA11974
  • Expected publication date: TBC

34709-Tucatinib-mFOLFOX6-Trastuzumab-for-HER2-Metastatic-Colorectal-Cancer-V1.0-DEC2025-NON-CONF-.pdf